Complement C4d 抗体
-
- 抗原 See all Complement C4d (C4d) products
- Complement C4d (C4d) (Complement Component C4d (C4d))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This Complement C4d antibody is un-conjugated
-
应用范围
- Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- 产品特性
- This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.
- 纯化方法
- Protein G affinity chromatography
- 免疫原
- Recombinant human C4d protein was used as the immunogen for this Complement 4d antibody.
- 克隆位点
- SPM545
- 亚型
- IgG1 kappa
-
-
- 应用备注
-
The optimal dilution of the Complement 4d antibody for each application should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. ELISA: 1-2 μg/mL (order BSA/azide free format),Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1),Prediluted format: incubate for 30 min at RT (2) - 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
- 储存液
- Azide free
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store the Complement 4d antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
- 抗原
- Complement C4d (C4d) (Complement Component C4d (C4d))
- 别名
- Complement 4d (C4d 产品)
- 背景
- This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.
-